Inactive Instrument
Allied Corp. Stock Other OTC
Stocks
ALID
US0191141078
Pharmaceuticals
OTC Markets Traded| Market Cap | 1.3M 1.14M 1.05M 983K 1.85M 123M 1.89M 12.66M 4.89M 60.78M 4.9M 4.79M 211M | P/E 2023 |
-2.13x | P/E 2024 | -2.52x |
|---|---|---|---|---|---|
| Enterprise Value | 7.55M 6.61M 6.1M 5.7M 10.72M 714M 10.96M 73.33M 28.31M 352M 28.36M 27.73M 1.22B | EV / Sales 2023 |
394,366,816x | EV / Sales 2024 | 171,944,593x |
| Free-Float |
52.84% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -5.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
Radka Milanova
CTO | Chief Tech/Sci/R&D Officer | 71 | - |
James Smeeding
PRN | Corporate Officer/Principal | - | 2020-05-01 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
James Smeeding
BRD | Director/Board Member | - | 2020-05-01 |
Abdul Nnyenje
BRD | Director/Board Member | - | 2024-10-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.00% | -5.00% | - | - | 117 | ||
| +2.12% | +2.84% | +338.18% | +19.01% | 2.64B | ||
| +2.78% | -8.51% | +162.50% | +135.71% | 1.73B | ||
| -10.91% | -19.72% | -27.70% | +109.67% | 459M | ||
| -2.08% | +4.44% | +20.51% | -6.00% | 51.65M | ||
| Average | -2.62% | -4.53% | +123.37% | +64.60% | 1.22B | |
| Weighted average by Cap. | +1.08% | -3.60% | +238.07% | +68.66% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 0.07 0.06 0.06 0.05 0.1 6.82 0.1 0.7 0.27 3.36 0.27 0.26 11.68 | 0.1 0.08 0.08 0.07 0.14 9.09 0.14 0.93 0.36 4.48 0.36 0.35 15.58 |
| Net income | -10.68M -9.35M -8.62M -8.05M -15.16M -1.01B -15.5M -104M -40.03M -498M -40.09M -39.21M -1.73B | -3.98M -3.48M -3.21M -3M -5.65M -376M -5.77M -38.62M -14.91M -185M -14.93M -14.6M -644M |
| Net Debt | 5.65M 4.95M 4.56M 4.26M 8.03M 534M 8.21M 54.89M 21.19M 264M 21.22M 20.76M 915M | 6.25M 5.47M 5.04M 4.71M 8.87M 591M 9.07M 60.67M 23.42M 291M 23.46M 22.95M 1.01B |
Employees
-
Sector
Pharmaceuticals
















